The drug is from a new class of antibiotics, the first new class in decades to be approved as a treatment for gonorrhea, ...

The U.S. Food and Drug Administration said on Thursday it has expanded the use of GSK's Blujepa as an oral treatment for ...

The FDA has proposed adding bemotrizinol, a new sunscreen ingredient, to the U.S. approval list, which could expand consumer ...

The narrow FDA labeling makes it so that only a minority of men who could benefit from treatment are considered ‘on-label’ ...

The U.S. is considering allowing bemotrizinol, a highly effective UV filter used throughout Europe and Asia, in its sunscreen ...

The Clean Label Boom Is Exploding Worldwide 1% in 2025. Honestly, those numbers tell us something powerful about where ...

Sibeprenlimab is approved for IgAN treatment, showing a 51.2% reduction in proteinuria in the VISIONARY trial. Administered subcutaneously every four weeks, it inhibits APRIL to reduce IgA levels.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

“It was a really hard sell,” recalls Druker, an oncologist and CEO of the Oregon Health & Science University Knight Cancer Institute, decades on. There were seemingly valid concerns at the time, he ...

The FDA has rejected Biohaven’s request for approval of a neurological disorder therapy, prompting the biopharma to reprioritize its pipeline in order to shrink its annual R&D spend by 60%. After a ...

Boehringer Ingelheim has secured FDA approval for its PDE4 inhibitor nerandomilast (Jascayd) for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. Nerandomilast ...

Revuforj, a menin inhibitor, is approved for relapsed/refractory NPM1-mutant AML, offering new hope for patients with limited treatment options. Blenrep combined with Velcade and dexamethasone ...